AACR 2021 | Modernization of clinical trial eligibility criteria

Alexander Spira • 7 Apr 2021

Real-World Data

Alex Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, shares his views on the need for modernization of clinical trial eligibility criteria, highlighting contrasting results from trials compared to real-world results, challenges around enrolment, and the importance of prioritizing safety. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

How will adagrasib fit into the treatment landscape of KRASG12-mutant NSCLC?

Alexander Spira • 4 Jun 2022

The evolving treatment landscape for NSCLC with EGFR exon 20 insertion mutations

Alexander Spira • 22 Sep 2021

Amivantamab for NSCLC with MET Exon 14 skipping mutations

Alexander Spira • 22 Sep 2021

KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC

Alexander Spira • 3 Jun 2022

Related Videos

The NCRI: supporting and expediting UK cancer research

Richard Stephens • 8 Nov 2018

Survivorship: the previously underfunded area in cancer research

Andrew Bottomley • 15 Nov 2018

IO-chemo and IO-radio options for cancer treatment

John Bell • 8 Nov 2018

Liquid biopsy assays: how best to use them

Kai-Keen Shiu • 9 Nov 2018